Journal
EMERGING INFECTIOUS DISEASES
Volume 27, Issue 10, Pages 2728-2731Publisher
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid2710.211538
Keywords
-
Categories
Ask authors/readers for more resources
This report demonstrates a novel mutation, Q493R, of the SARS-CoV-2 spike protein that confers resistance to both bamlanivimab and etesivimab, isolated from a patient who had received treatment with these drugs.
We report in vivo selection of a severe acute respiratory syndrome coronavirus 2 spike mutation (Q493R) conferring simultaneous resistance to bamlanivimab and etesivimab. This mutation was isolated from a patient who had coronavirus disease and was treated with these drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available